Teva converts Copaxone users

Share this article:

Generic Copaxone may not gut Teva's earnings if the drugmaker continues to convert users to its latest formulation. “'We may have failed to understand just how comprehensive Teva's patient outreach system has been,” Cowen analyst Ken Cacciatore tells Bloomberg Businessweek.

Businessweek reports that Teva has managed to migrate 8.7% of its 20mg prescriptions to the new, three-times-a week 40mg version of the MS drug as of February 28.

Teva anticipated that generic Copaxone could inflict serious damage on its outlook, so much so that its 2014 guidance included life-with and life-without generic Copaxone numbers.

Teva said in December that every month without generic Copaxone enriches it by $78 million. Bloomberg reported at the time that the generic could push Teva into its first sales drop in two decades.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.